SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) / sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). 6. Juni 2014 Weikersthal, L.F. von, Goebell, P.J., de Santis, M. de, Lerchenmüller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., van Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., Michel, M.S., 2014. Oncol Res Treat 37 (suppl 5)(V28), 5. doi:10.1159/000368945 Abstract Prognostic factors for overall survival in patients with advanced NSCLC – data from the clinical registry on lung cancer (TLK). von Verschuer, U., Tessen, H.W., Eggert, J., Neise, M., Frank, M., Jänicke, M., Spring, L., Marschner, N., 2014. Oncol Res Treat 37 (suppl 5)(V701), 227. Weiterlesen Chemotherapy, targeted therapy and anti-hormonal therapy of elderly patients with breast cancer – data from the SENORA project. Zahn, M.-O., Tesch, H., Köhler, A., Fietz, T., Münz, M., Kruggel, L., Jänicke, M., Marscher, N., 2014. Oncol Res Treat 37 (suppl 5)(V374), 112. doi:10.1159/000368945… Weiterlesen